Medtech gears up for a vintage acquisition year
Device deal making is back in a big way, despite the munificence of venture funds.
Role reversal for large-cap medtechs
Shareholders are rewarding the kinds of companies they punished a year ago.
Diasorin heads to the US with $1.8bn Luminex deal
And consolidation in the diagnostics space is only just beginning.
US cuts fees for Covid-19 tests
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
US pursues pooled testing for Covid-19, and Quest benefits
Batch testing could allow large numbers of people to be ruled out as having Covid-19, but accuracy concerns remain.
Covid-19 divides the biggest medtechs
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
The importance of testing Covid-19 tests
The US is authorising new Covid-19 antibody tests faster than it is checking their accuracy.
